TherapeuticsMD (TXMD) Misses Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
TherapeuticsMD Announces Third Quarter 2021 Financial Results
November 11, 2021 6:50 AM EST- Quarterly total net product revenue of $24.5 million, an increase of 41.1% over Q3 2020 -
- ANNOVERA® TRx of 8,351, an increase of 62.7% over Q3 2020 -
- Cost savings initiative to reduce SG&A by $40 million in 2022; anticipated additional savings of approximately $20 million annualized tied to the divestiture of vitaCare -
- Hugh ODowd, President, to become Chief Executive Officer; Robert Finizio appointed Vice Chair of the Board -
- Conference call scheduled for 8:30 a.m. ET today -
BOCA RATON, Fla.--(BUSINESS... More
